Medtronic

TriMed Staff | | Cardiovascular Business | Patient Care
Medtronic (Booth 826) is featuring clinical research updates from its international RESOLUTE trials, designed to assess the safety and efficacy of its Endeavor Resolute drug-eluting stent (DES) system, which is an investigational device in the U.S., but commercially available in Europe.

Clinical research teams led by interventional cardiologists James Carr, MD, at East Texas Medical Center in the United States and Prof. Dr. Franz-Josef Neumann at the Heart Center of Bad Krozingen in Germany are enrolling patients in RESOLUTE US (R-US) and RESOLUTE International (R-Int), respectively. 

The Endeavor Resolute DES uses the proprietary BioLinx polymer, which was designed to meet the same biocompatibility requirements as the phosphorylcholine (PC) polymer used in Medtronic's Endeavor stent. Compared to the PC polymer, the BioLinx polymer is designed to extend the duration of drug exposure in the vessel.

TriMed Staff

Related Content

Early pregnancy blood pressure patterns tied to hypertension risk years later
Enabling X-ray-free ablation procedures in the EP lab
Detecting coronary inflammation on CT imaging could reshape preventive cardiology
Know your options: What cardiologists recommend when alternative access is required for TAVR
New drug therapies targeting Lp(a) could be a breakthrough in cardiovascular care
Getinge ending production of cardiopulmonary surgical perfusion systems

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.